Serum VEGF-A as a biomarker for the addition of bevacizumab to chemo-immunotherapy in metastatic NSCLC.

Tanaka K, Sugisaka J, Shiraishi Y, Watanabe Y, Daga H, Azuma K, Nishino K, Mori M, Ota T, Saito H, Hata A, Sakaguchi T, Kozuki T, Akamatsu H, Matsumoto H, Tachihara M, Wakuda K, Sato Y, Ozaki T, Tsuchiya-Kawano Y, Yamamoto N, Nakagawa K, Okamoto I

Open source

DOI: 10.1038/s41467-025-58186-7
Published: 2025 Mar 22
Container: Nature communications
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1038/s41467-025-58186-7,
  title = {Serum VEGF-A as a biomarker for the addition of bevacizumab to chemo-immunotherapy in metastatic NSCLC.},
  author = {Tanaka K and Sugisaka J and Shiraishi Y and Watanabe Y and Daga H and Azuma K and Nishino K and Mori M and Ota T and Saito H and Hata A and Sakaguchi T and Kozuki T and Akamatsu H and Matsumoto H and Tachihara M and Wakuda K and Sato Y and Ozaki T and Tsuchiya-Kawano Y and Yamamoto N and Nakagawa K and Okamoto I},
  year = {2025},
  journal = {Nature communications},
  doi = {10.1038/s41467-025-58186-7},
  url = {https://doi.org/10.1038/s41467-025-58186-7}
}

RIS

TY  - JOUR
TI  - Serum VEGF-A as a biomarker for the addition of bevacizumab to chemo-immunotherapy in metastatic NSCLC.
AU  - Tanaka K
AU  - Sugisaka J
AU  - Shiraishi Y
AU  - Watanabe Y
AU  - Daga H
AU  - Azuma K
AU  - Nishino K
AU  - Mori M
AU  - Ota T
AU  - Saito H
AU  - Hata A
AU  - Sakaguchi T
AU  - Kozuki T
AU  - Akamatsu H
AU  - Matsumoto H
AU  - Tachihara M
AU  - Wakuda K
AU  - Sato Y
AU  - Ozaki T
AU  - Tsuchiya-Kawano Y
AU  - Yamamoto N
AU  - Nakagawa K
AU  - Okamoto I
PY  - 2025
JO  - Nature communications
DO  - 10.1038/s41467-025-58186-7
UR  - https://doi.org/10.1038/s41467-025-58186-7
ER  -

APA

K, T., J, S., Y, S., Y, W., H, D., K, A., K, N., M, M., T, O., H, S., A, H., T, S., T, K., H, A., H, M., M, T., K, W., Y, S., T, O., Y, T., N, Y., K, N., & I, O. (2025). Serum VEGF-A as a biomarker for the addition of bevacizumab to chemo-immunotherapy in metastatic NSCLC.. Nature communications. https://doi.org/10.1038/s41467-025-58186-7

Source records

pubmed · retrieved 2026-09-25T23:12:57.682Z